• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    2/13/23 4:58:04 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    SC 13G/A 1 d466563dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    (Amendment No. 1)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

     

    LENSAR, Inc.

    (Name of Issuer)

    Common Stock, $0.01 par value

    (Title of Class of Securities)

    52634L108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

     


    CUSIP No. 52634L108

     

      1    

      NAME OF REPORTING PERSONS

     

      North Run Capital, LP

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,096,406*

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,096,406**

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,096,406**

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.95%**

    12  

      TYPE OF REPORTING PERSON*

     

      PN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4.


    CUSIP No. 52634L108

     

      1    

      NAME OF REPORTING PERSONS

     

      North Run Advisors, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,096,406**

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,096,406**

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,096,406**

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.95%**

    12  

      TYPE OF REPORTING PERSON*

     

      OO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4.


    CUSIP No. 52634L108

     

      1    

      NAME OF REPORTING PERSONS

     

      Todd B. Hammer

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,096,406**

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,096,406**

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,096,406**

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.95%**

    12  

      TYPE OF REPORTING PERSON*

     

      IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4.


    CUSIP No. 52634L108

     

      1    

      NAME OF REPORTING PERSONS

     

      Thomas B. Ellis

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

      SOLE VOTING POWER

     

      0

       6  

      SHARED VOTING POWER

     

      1,096,406**

       7  

      SOLE DISPOSITIVE POWER

     

      0

       8  

      SHARED DISPOSITIVE POWER

     

      1,096,406**

      9    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,096,406**

    10  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

      ☐

    11  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      9.95%**

    12  

      TYPE OF REPORTING PERSON*

     

      IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4.


    AMENDMENT NO. 1 TO SCHEDULE 13G

    This Amendment No. 1 to Schedule 13G (this “Amendment”) is being filed on behalf of North Run Capital, LP, a Delaware limited partnership (the “Investment Manager”), North Run Advisors, LLC, a Delaware limited liability company (“North Run”), Todd B. Hammer and Thomas B. Ellis (collectively, the “Reporting Persons”). Todd B. Hammer and Thomas B. Ellis are the principals and sole members of North Run. North Run is the general partner of the Investment Manager. The Investment Manager is the investment manager of certain private pooled investment vehicles (collectively, the “Funds”). This Amendment relates to shares of Common Stock, $0.01 par value (the “Common Stock”), of LENSAR, Inc., a Delaware corporation (the “Issuer”), held by the Funds.

     

    Item 1(a)

    Name of Issuer.

    LENSAR, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices.

    2800 Discovery Drive

    Orlando, Florida 32826

     

    Item 2(a)

    Name of Person Filing.

     

      (1)

    North Run Capital, LP

     

      (2)

    North Run Advisors, LLC

     

      (3)

    Todd B. Hammer

     

      (4)

    Thomas B. Ellis

     

    Item 2(b)

    Address of Principal Business Office, or, if none, Residence.

    For all Filers:

    867 Bolyston St.

    5th Floor #1361

    Boston, MA 02116

     

    Item 2(c)

    Citizenship or Place of Organization.

     

      (1)

    North Run Capital, LP is a Delaware limited partnership.

     

      (2)

    North Run Advisors, LLC is a Delaware limited liability company.

     

      (3)

    Todd B. Hammer is a U.S. citizen.

     

      (4)

    Thomas B. Ellis is a U.S. citizen.

     

    Item 2(d)

    Title of Class of Securities.

    Common Stock, $0.01 par value.

     

    Item 2(e)

    CUSIP Number.

    52634L108


    Item 3

    Reporting Person.

    Inapplicable

     

    Item 4

    Ownership.

     

    (a)

    The Investment Manager, North Run, Todd B. Hammer and Thomas B. Ellis may be deemed the beneficial owners of 1,096,406 shares of Common Stock.

     

    (b)

    The Investment Manager, North Run, Todd B. Hammer and Thomas B. Ellis may be deemed the beneficial owners of 9.95% of the outstanding shares of Common Stock. This percentage was determined by dividing 1,096,406 by 11,023,304, which is the number of shares of Common Stock outstanding as of October 31, 2022, according to the Issuer’s Form 10-Q filed on November 9, 2022 with the Securities and Exchange Commission.

     

    (c)

    The Investment Manager, North Run, Todd B. Hammer and Thomas B. Ellis have the shared power to vote and dispose of the 1,096,406 shares of Common Stock beneficially owned.

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    Inapplicable

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person.

    Inapplicable.

     

    Item 7

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

    Inapplicable

     

    Item 8

    Identification and Classification of Members of the Group.

    Inapplicable

     

    Item 9

    Notice of Dissolution of Group.

    Inapplicable

     

    Item 10

    Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2023

     

    NORTH RUN CAPITAL, LP
    By:  

    North Run Advisors, LLC

    its general partner

             By:   /s/ Thomas B. Ellis*
        Name: Thomas B. Ellis
        Title: Member
      and
      By:   /s/ Todd B. Hammer*
        Name: Todd B. Hammer
        Title: Member
    NORTH RUN ADVISORS, LLC
    By:   /s/ Thomas B. Ellis*
      Name: Thomas B. Ellis
      Title: Member
    and
    By:   /s/ Todd B. Hammer*
      Name: Todd B. Hammer
      Title: Member
    /s/ Thomas B. Ellis*
    Thomas B. Ellis
    /s/ Todd B. Hammer*
    Todd B. Hammer
    * By   /s/ MICHAEL FISHER
      Michael Fisher, Attorney-in-Fact Pursuant to Powers of Attorney filed as exhibits hereto
    Get the next $LNSR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    SEC Filings

    View All

    SEC Form 10-Q filed by LENSAR Inc.

    10-Q - LENSAR, Inc. (0001320350) (Filer)

    8/7/25 4:05:33 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LENSAR, Inc. (0001320350) (Filer)

    8/7/25 7:15:25 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LENSAR, Inc. (0001320350) (Filer)

    7/2/25 4:00:35 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    3/2/21 8:10:50 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    2/24/21 6:12:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ellis Thomas B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/28/25 4:57:30 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Hammer Todd B was granted 7,374 shares, increasing direct ownership by 24% to 38,662 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/28/25 4:56:24 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M was granted 7,374 shares, increasing direct ownership by 9% to 88,214 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    5/28/25 4:30:14 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the new empl

    7/1/25 4:01:11 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports First Quarter 2025 Results and Provides Business Update

             14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

    5/8/25 7:00:42 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

    2/27/25 7:00:11 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care